Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONTO-Time in Range
NCT04605991Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of insulin lispro in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 mg/dL During Daytime Period at 12 weeks. Started Nov 2020; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04605991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605991.